Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTA-H19/PEI in Intermediate-Risk Superficial Bladder Cancer
NCT00595088Phase 2Completed
- Sponsor
- Anchiano Therapeutics Ltd.
- Start
- Jan 2008
- Primary completion
- Jan 2013
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of inodiftagene vixteplasmid in bladder cancer, sponsored by Anchiano Therapeutics Ltd.. Started Jan 2008; status: completed.
02
Drugs
inodiftagene vixteplasmid
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00595088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595088.